Price (delayed)
$7.53
Market cap
$236M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.81
Enterprise value
$159.53M
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative,
There are no recent dividends present for CABA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.